YU-MEI CHEN: Open Payments
NPI 1649746736 · MANCHESTER, NH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$658 in 34 payments from 10 companies in 2025. Trend: 2023 $615 · 2024 $581 · 2025 $658
Food & beverage: $658
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 16 | $300 |
| Neurocrine BioSciences, Inc. | 5 | $98 |
| E.R. Squibb & Sons, L.L.C. | 3 | $83 |
| Otsuka America Pharmaceutical, Inc. | 3 | $48 |
| Janssen Pharmaceuticals, Inc | 2 | $34 |
| Becton, Dickinson and Company | 1 | $24 |
| Alkermes, Inc. | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| ABBVIE INC. | 1 | $16 |
| Lundbeck LLC | 1 | $15 |
Products named: FANAPT, INGREZZA, COBENFY, REXULTI, INVEGA SUSTENNA, ARISTADA, TRINTELLIX, VRAYLAR.
Industry payments across NH — which companies pay providers there.
